Clinical Trials Browser

Agammaglobulinemia × Panzyga × 30 days × Clear all

NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Phase 3 Completed

LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell